Hui‐May Chu

1.4k total citations · 1 hit paper
21 papers, 1.0k citations indexed

About

Hui‐May Chu is a scholar working on Oncology, Pharmacology and Psychiatry and Mental health. According to data from OpenAlex, Hui‐May Chu has authored 21 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Pharmacology and 5 papers in Psychiatry and Mental health. Recurrent topics in Hui‐May Chu's work include Hepatitis C virus research (5 papers), Statistical Methods in Clinical Trials (5 papers) and Statistical Methods and Bayesian Inference (4 papers). Hui‐May Chu is often cited by papers focused on Hepatitis C virus research (5 papers), Statistical Methods in Clinical Trials (5 papers) and Statistical Methods and Bayesian Inference (4 papers). Hui‐May Chu collaborates with scholars based in United States, Netherlands and Germany. Hui‐May Chu's co-authors include Stefan Zeuzem, Christine J. Weegink, Tara L. Kieffer, Doug J. Bartels, Chao Lin, Ute Müh, Ann D. Kwong, Brian L. Hanzelka, Yi Zhou and Christoph Sarrazin and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Hepatology.

In The Last Decade

Hui‐May Chu

20 papers receiving 977 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir

2007 476 citations Christoph Sarrazin, Tara L. Kieffer et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hui‐May Chu United States	9	739	597	311	114	78	21	1.0k
Jens Kort United States	17	905 1.2×	717 1.2×	407 1.3×	129 1.1×	108 1.4×	61	1.4k
René Verloes Belgium	15	301 0.4×	406 0.7×	260 0.8×	119 1.0×	43 0.6×	44	849
Carlos A. Luciano United States	15	153 0.2×	328 0.5×	244 0.8×	174 1.5×	119 1.5×	32	1.3k
Jean‐Maurice Dumont Switzerland	13	481 0.7×	383 0.6×	198 0.6×	588 5.2×	20 0.3×	14	1.1k
F. Keller France	8	319 0.4×	286 0.5×	94 0.3×	54 0.5×	21 0.3×	16	521
Ilia Toshkov United States	17	309 0.4×	371 0.6×	80 0.3×	201 1.8×	5 0.1×	28	928
Rakesh Bhat Canada	10	105 0.1×	174 0.3×	42 0.1×	252 2.2×	27 0.3×	27	630
Xueen Liu China	16	484 0.7×	584 1.0×	92 0.3×	339 3.0×	7 0.1×	38	964
Amy Paulino United States	10	72 0.1×	144 0.2×	123 0.4×	119 1.0×	46 0.6×	12	677
Paloma Muñoz de Rueda Spain	11	191 0.3×	228 0.4×	40 0.1×	150 1.3×	38 0.5×	24	546

Countries citing papers authored by Hui‐May Chu

Since Specialization

Citations

This map shows the geographic impact of Hui‐May Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hui‐May Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hui‐May Chu more than expected).

Fields of papers citing papers by Hui‐May Chu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hui‐May Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hui‐May Chu. The network helps show where Hui‐May Chu may publish in the future.

Co-authorship network of co-authors of Hui‐May Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Hui‐May Chu. A scholar is included among the top collaborators of Hui‐May Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hui‐May Chu. Hui‐May Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alam, John, Paul Maruff, Susan R. Doctrow, et al.. (2023). Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies. Neurology. 101(17). e1708–e1717. 16 indexed citations

Prins, Niels D., et al.. (2021). A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease. Alzheimer s Research & Therapy. 13(1). 106–106. 69 indexed citations

Tolbert, Dwain, Hui‐May Chu, & Ene Ette. (2019). Pharmacometrics of clobazam in pediatrics: Prediction of effective clobazam doses for Dravet syndrome. Epilepsy Research. 157. 106182–106182. 2 indexed citations

Tolbert, Dwain, Hui‐May Chu, & Ene Ette. (2018). Pharmacometrics of Clobazam in Pediatrics: Population PK Modeling to Predict Effective Clobazam Doses for Dravet Syndrome (P4.265). Neurology. 90(15_supplement). 1 indexed citations

Manak, Michael S., Nikhil S. Joshi, Hui‐May Chu, et al.. (2018). Live-cell phenotypic-biomarker microfluidic assay for the risk stratification of cancer patients via machine learning. Nature Biomedical Engineering. 2(10). 761–772. 61 indexed citations

Scheltens, Philip, Niels D. Prins, Adriaan A. Lammertsma, et al.. (2018). An exploratory clinical study of p38α kinase inhibition in Alzheimer's disease. Annals of Clinical and Translational Neurology. 5(4). 464–473. 50 indexed citations

Tolbert, Dwain, Ihor Bekersky, Hui‐May Chu, & Ene Ette. (2015). Clobazam Drug-Drug Interactions: A Mechanism-Based Characterization Using a Model-Based Approach (P4.259). Neurology. 84(14_supplement).

Tolbert, Dwain, Ihor Bekersky, Hui‐May Chu, & Ene Ette. (2015). An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokinetics. The Journal of Clinical Pharmacology. 56(2). 213–222. 7 indexed citations

Tolbert, Dwain, Ihor Bekersky, Hui‐May Chu, & Ene Ette. (2015). Drug‐metabolism mechanism: Knowledge–based population pharmacokinetic approach for characterizing clobazam drug‐drug interactions. The Journal of Clinical Pharmacology. 56(3). 365–374. 14 indexed citations

10.

Yan, Feng, et al.. (2012). Characterization of ipilimumab exposure-efficacy/safety response relationships in subjects with previously treated or untreated advanced melanoma.. Journal of Clinical Oncology. 30(15_suppl). 8541–8541. 1 indexed citations

11.

Chu, Hui‐May, Jiuhong Zha, Amit Roy, & Ene Ette. (2008). Determination of the Efficiency of First Time-In-Man Designs in Healthy Volunteers. Clinical Research and Regulatory Affairs. 25(3). 157–172. 2 indexed citations

12.

Neumann, Avidan U., et al.. (2007). [625] NOVEL MODE OF VIRAL DECLINE DURING TELAPREVIR (VX-950) AND PEG-IFN COMBINATION TREATMENT PREDICTED BY A NEW COMBINED INTRACELLULAR AND CELLULAR HEPATITIS C VIRAL DYNAMICS MODEL. Journal of Hepatology. 46. S236–S236. 1 indexed citations

13.

Forestier, Nicole, Hendrik W. Reesink, Christine J. Weegink, et al.. (2007). Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology. 46(3). 640–648. 189 indexed citations

14.

Sarrazin, Christoph, Tara L. Kieffer, Doug J. Bartels, et al.. (2007). Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir. Gastroenterology. 132(5). 1767–1777. 476 indexed citations breakdown →

15.

Chu, Hui‐May, et al.. (2007). [609] TELAPREVIR (VX 950)-RESISTANT VARIANTS EXHIBIT REDUCED REPLICATION CAPACITY COMPARED TO WILD-TYPE HCV IN VIVO AND IN VITRO. Journal of Hepatology. 46. S230–S231. 6 indexed citations

16.

Zhou, Yi, Doug J. Bartels, Brian L. Hanzelka, et al.. (2007). Phenotypic Characterization of Resistant Val³⁶Variants of Hepatitis C Virus NS3-4A Serine Protease. Antimicrobial Agents and Chemotherapy. 52(1). 110–120. 79 indexed citations

17.

Reesink, H.W., Christine J. Weegink, Stefan Zeuzem, et al.. (2006). 737 Initial results of a 14-day study of the hepatitis C virus inhibitor protease VX-950, in combination with peginterferon-alpha-2a. Journal of Hepatology. 44. S272–S272. 20 indexed citations

18.

Chu, Hui‐May & Ene Ette. (2005). A random sampling approach for robust estimation of tissue-to-plasma ratio from extremely sparse data. The AAPS Journal. 7(1). E249–E258. 3 indexed citations

19.

Ette, Ene, Hui‐May Chu, & Christopher Godfrey. (2005). Data Supplementation: A Pharmacokinetic/Pharmacodynamic Knowledge Creation Approach for Characterizing an Unexplored Region of the Response Surface. Pharmaceutical Research. 22(4). 523–531. 2 indexed citations

20.

Chu, Hui‐May & Lynn Kuo. (1997). Sampling based approach for one-hit and multi-hit models in quantal bioassay. Statistics and Computing. 7(3). 183–192. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact